Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Diamondback Energy Inc (FANG) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Diamondback Energy IncTrade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

Diamondback Energy Inc vs IDEXX Laboratories, Inc. — how do they compare? Diamondback Energy Inc trades at $192.13 (market cap $53.67B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: Diamondback Energy Inc is the larger of the two by market cap, and Diamondback Energy Inc pays a 2.3% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 69 Days and IDEXX Laboratories, Inc. for 46 Days on average.

FANGIDXX
Market Cap
$53.67B$40.43B
Volume
2,250,644692,164
Sector
EnergyHealth
52-Week High
$213.69$766.68
52-Week Low
$137.29$504.70
Typical Hold Time
69 Days46 Days
Enterprise Value
$65.83B$41.32B
Dividend Yield
2.3%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Diamondback Energy Inc

Diamondback Energy (FANG) trades at $191.68, up 3.96% today, with strong analyst support (90.57% buy rating) and a $231.77 consensus price target. The stock shows bullish technical momentum above key support at $189, while fundamentals reveal robust revenue growth from $14.93B in 2025 to projected $17.0B in 2026, though net margins have compressed. Recent Q2 2026 earnings beat expectations at $6.48 EPS, and the company maintains solid cash flow generation with $8.76B from operations in 2025.

FANG presents a compelling growth opportunity with Permian Basin dominance and positive earnings momentum, but investors face risks from oil price volatility and insider selling. The stock's current valuation at 36.51 P/E requires sustained execution to justify upside, while technical indicators suggest near-term resistance at $193-197 levels.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.

Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FANG
100% Buy0% Sell
Avg holding period · 69 Days
IDXX

No sentiment data available yet.

About Diamondback Energy Inc

Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.

Read more on FANG →

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX →